Welcome to our dedicated page for Pharvaris N.V. SEC filings (Ticker: PHVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pharvaris N.V. filings document foreign private issuer disclosures for a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists. Form 6-K reports furnish financial results, business updates, investor presentations, clinical-study updates, annual general meeting voting results and materials incorporated by reference into Form F-3 and Form S-8 registration statements.
The filing record also covers capital-structure activity involving ordinary shares and pre-funded warrants, registration rights agreements, underwriting documents, share-based compensation and governance matters. These disclosures frame Pharvaris' development-stage operating expenses, financing activity, shareholder approvals and formal reporting obligations as a Nasdaq-listed foreign private issuer.
Pharvaris N.V.’s Chief Medical Officer Lu Peng reported a small, scheduled option exercise and share sale. On June 18, 2026, Peng exercised stock options to acquire 300 shares of common stock at $2.59 per share and sold 300 common shares at $34.00 per share in an open-market transaction.
The filing states this was done under a Rule 10b5-1 trading plan. After these transactions, Peng directly holds 65,631 common shares and 205,008 stock options with a $2.59 exercise price expiring on February 3, 2030, indicating the sale involved only a small portion of the overall position.
PHVS-related filing: A Form 144 reports the proposed sale following an exercise of 300 common shares on 06/18/2026. The filing also lists recent Rule 10b5-1 sales in Apr–May 2026, with individual transactions such as 14,166 shares on 05/01/2026.
Pharvaris N.V. director and Chief Executive Officer Berndt Modig reported small open-market sales of company common stock. On June 15, 2026, he sold a total of 2,291 shares in two transactions at weighted average prices of about $31.05 and $31.46 per share, executed under a Rule 10b5-1 trading plan. The filing notes that the sold shares included stock previously acquired through vesting of restricted stock units. Following these sales, Modig holds 135,209 shares directly and 950,000 shares indirectly through Schoodic Management BV, an entity he controls.
Pharvaris N.V. Chief Medical Officer Lu Peng had 117 shares of Common Stock withheld on June 12, 2026 to cover tax obligations from vesting restricted stock units. The shares were valued at $32.20 each based on fair market value, and Peng now directly holds 65,631 shares.
Pharvaris N.V. Chief Medical Officer Lu Peng reported a small share disposition tied to equity compensation. On the vesting of restricted stock units on June 11, 2026, 109 shares of common stock were withheld to cover tax withholding obligations at a fair market value of $31.51 per share. After this tax-withholding event, Lu Peng directly owns 65,748 shares of Pharvaris common stock, so the filing reflects routine administration of stock-based compensation rather than an open-market trade.
PHVS notice: a brokered Rule 144 submission lists 2,291 Restricted Stock Units dated 06/11/2026 proposed for sale and records recent 10b5-1 sales by Berndt B.A.E. Modig on 05/15/2026, 04/16/2026, and 04/08/2026 with proceeds of $68,581.68, $65,558.53, and $647,283.26 respectively.
Pharvaris N.V. has called its annual general meeting for June 26, 2026 in Amsterdam and circulated the 2025 Dutch statutory annual accounts and board report. Shareholders will vote on adopting the 2025 accounts, appointing PricewaterhouseCoopers as 2026 auditor, renewing a share repurchase authorization of up to 10% of issued capital for 18 months, and re-appointing Dr. Margareta Elisabeth Björk as a non-executive director.
The company reiterates its focus on deucrictibant, an oral bradykinin B2 receptor antagonist for hereditary and acquired angioedema. A pivotal Phase 3 on-demand study (RAPIDe-3) met its primary and all key secondary endpoints, and Pharvaris plans to submit a New Drug Application in the first half of 2026. A global Phase 3 prophylaxis study (CHAPTER-3) of the extended-release tablet is ongoing with topline data anticipated in the third quarter of 2026, alongside the CREAATE Phase 3 program in acquired angioedema.
Pharvaris N.V. principal accounting officer Anna Nijdam sold 2,670 shares of common stock in an open-market transaction on June 4, 2026, at a weighted average price of about $30.87 per share. The shares sold were acquired upon vesting of restricted stock units, and she continues to hold 46,275 shares directly after the sale.
PHVS reporting under Rule 144: notices list proposed sales of Common Stock tied to restricted stock grants and two recent dispositions by Anna Nijdam. The filing shows restricted stock grant quantities of 1,578 (10/01/2021) and 1,092 (10/01/2022), and reported sales of 5,501 shares on 05/22/2026 for $169,084.24 and 1,829 shares on 05/21/2026 for $55,971.24.
Pharvaris N.V. director Viviane Monges sold 9,667 shares of Common Stock in an open-market transaction. The sale occurred on May 21, 2026 at a weighted average price of $30.2941 per share, with individual trade prices ranging from $30.08 to $30.49 per share.
The shares sold were previously acquired upon vesting of restricted stock units granted as equity compensation. Following this transaction, Monges directly holds 5,500 Pharvaris shares. A footnote also corrects prior beneficial ownership reported on a Form 3, which had understated holdings by 513 shares due to earlier administrative errors in tax-withholding records.